Bienaime Jean Jacques's Form 4 filing
Biomarin Pharmaceutical Inc (BMRN) · filed Jan 14, 2022
- Accession no.
- 0001567619-22-001225
- Filed
- Jan 14, 2022
- Trade date
- Dec 21, 2021-Jan 13, 2022
- Filing delay
- 24 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $884.3K. It was filed 24 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bienaime Jean JacquesCIK 0001221590 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 21, 2021 | Common Stock | LLess common codeAcquired | +100 | $89.22 | +$8,922 | 303,789 | Direct | |
| Jan 12, 2022 | Common Stock | MOption exerciseAcquired | +5,000 | $37.46 | +$187,300 | 308,789 | Direct | |
| Jan 12, 2022 | Common Stock | SSaleDisposed | −5,000 | $89.00 | −$445,000 | 303,789 | Direct | |
| Jan 13, 2022 | Common Stock | MOption exerciseAcquired | +5,000 | $37.46 | +$187,300 | 308,789 | Direct | |
| Jan 13, 2022 | Common Stock | SSaleDisposed | −5,000 | $87.86 | −$439,300 | 303,789 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2022 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 120,000 | Direct | |
| Jan 13, 2022 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 115,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.